Psoriasis is a common chronic inflammatory skin condition that affects 3% to 4% of adults in the United States. Genetic susceptibility, immune dysregulation, and environmental factors are all thought to play a role in the development of the condition. Immunopathogenic studies have revealed that tumor necrosis factor alpha (TNF-α) and interleukins (IL-12, IL-17, IL-22, IL-23) are key cytokines involved in the pathogenesis of psoriasis. In recent years, there has been a focus on the development of treatment agents targeting these inflammatory cytokines. Despite the availability of effective treatments for psoriasis, physicians often fail to recognize psoriasis as a systemic inflammatory disease, resulting in significant undertreatment. Specifically, moderate and severe psoriasis are often treated with topical agents rather than more potent biologic and oral treatments, contributing to suboptimal outcomes and poor patient satisfaction.
In this CME Outfitters webinar, participants will be presented with a real-world case scenario intermixed with nationally-known, expert faculty discussing the latest clinical data, guidelines, and quality measures and how they apply to the case as we add layers of complexity to our patient scenario. Finally, faculty will discuss creating personalized clinical action plans for patients with psoriasis and take questions during dedicated time for Q & A.